Patent intelligence · US
US 2025388678
Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer
Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer
Patent details — US 2025388678
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 25, 2025
- Expiration
- Dec 20, 2045
- Applicant
- ASTRAZENECA AB [SE]
- CPC classes
- A61K 31/ 555 A I, A61K 31/ 7068 A I, A61K 39/ 00 A I, A61K/31555
Quick answer
US 2025388678 (Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Dec 25, 2025. Expires Dec 20, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTRAZENECA AB [SE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 555 A I, A61K 31/ 7068 A I, A61K 39/ 00 A I, A61K/31555, A61K/317068, A61K/33243
More from ASTRAZENECA AB [SE]
Related pharmaceutical patents in our USPTO index.
-
WO 2026115454
ANTICORPS ANTI-CLAUDINE 18.2, FRAGMENTS DE LIAISON À L'ANTIGÈNE ET CONJUGUÉS ANTICORPS-MÉDICAMENT ASSOCIÉS ET MÉTHODES D'UTILISATION DANS UNE THÉRAPIE ANTICANCÉREUSE
granted -
WO 2026109729
COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN
granted -
WO 2026104647
VACCIN
granted -
WO 2026094002
COMBINAISONS DE MOLÉCULES D'ACTIVATION DE LYMPHOCYTES T BISPÉCIFIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE TUMEURS SOLIDES EXPRIMANT CLAUDINE 18.2
granted -
WO 2026093539
MÉTHODES DE TRAITEMENT OU DE GESTION DE L'OBÉSITÉ
granted -
WO 2026093542
TRAITEMENT D'ASSOCIATION D'UN AGONISTE DU GLP1R ET D'UN INHIBITEUR DU SGLT-2
granted -
WO 2026093537
MÉTHODES DE TRAITEMENT DU DIABÈTE
granted -
WO 2026093541
SCHÉMAS POSOLOGIQUES POUR L'AZD5004
granted
Frequently asked questions
What is US patent 2025388678?
US 2025388678 (Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Dec 25, 2025. Expires Dec 20, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2025388678?
ASTRAZENECA AB [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2025388678 expire?
Our index shows an expiration date of Dec 20, 2045 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.